



ISSN NO. 2320-5407

ISSN: 2320-5407

International Journal of Advanced Research

Publisher's Name: Jana Publication and Research LLP

www.journalijar.com

REVIEWER'S REPORT

Manuscript No.: IJAR- 50587

Date: 10/03/2025

Title: "The Role of Sugammadex in Thoracic Surgery: A Comprehensive Review"

Recommendation:

- ✓ Accept as it is
- Accept after minor revision.....
- Accept after major revision
- Do not accept (*Reasons below*)

Rating	Excel.	Good	Fair	Poor
Originality		✓		
Techn. Quality		✓		
Clarity		✓		
Significance		✓		

Reviewer Name: Dr. S. K. Nath

Date: 12/03/2025

Reviewer's Comment for Publication:

This research paper effectively highlights sugammadex as a game-changer in thoracic anesthesia. Its ability to provide rapid and reliable NMB reversal makes it superior to neostigmine, particularly in high-risk patients. The clinical cases presented support sugammadex's efficacy, but further large-scale trials are needed to validate these findings. Additionally, a more in-depth cost-benefit analysis and exploration of long-term outcomes would enhance the paper's impact. Overall, this paper is a strong contribution to the field of anesthesiology and perioperative care.

Reviewer's Comment / Report

Strengths of the Paper

- 1. Clear and Well-Structured Content:** The paper is well-organized, beginning with an abstract that succinctly summarizes the key points. The introduction provides a strong background on the importance of neuromuscular blockade (NMB) reversal in thoracic surgery. The discussion effectively compares sugammadex to neostigmine, reinforcing its advantages with references to previous studies.
- 2. Comprehensive Coverage:** It covers various thoracic procedures such as thymectomy, lobectomy, bronchoscopy, and airway emergencies, offering a broad perspective on sugammadex's clinical applications. The inclusion of multiple case studies enhances credibility and demonstrates real-world effectiveness.
- 3. Strong Use of Evidence:** The paper is well-supported by citations from clinical studies and trials, lending it scientific rigor. Figures and tables help illustrate the differences between sugammadex and traditional reversal agents, making the data more accessible.
- 4. Clinical Relevance:** The discussion on postoperative complications, patient safety, and cost-effectiveness is particularly valuable for anesthesiologists and surgeons. The inclusion of special populations (e.g., myasthenia gravis patients) highlights sugammadex's utility in high-risk cases.

REVIEWER'S REPORT

Areas for Improvement

- 1. Case Study Limitations:** While case studies provide valuable insights, the paper lacks large-scale statistical analyses that would offer stronger generalizability. The selection bias in case studies (excluding patients with renal impairments) should be acknowledged more explicitly.
- 2. Economic Considerations Need More Depth:** The discussion of cost-effectiveness is relatively brief. More data on healthcare savings (e.g., shorter ICU stays, reduced complications) would strengthen the argument for sugammadex.
- 3. Long-Term Outcomes Are Not Addressed:** While the paper effectively discusses immediate postoperative recovery, it does not explore long-term outcomes such as 30-day mortality or readmission rates.